Stay updated with breaking news from Lantern Pharma. Get real-time updates on events, politics, business, and more. Visit us for reliable news and exclusive interviews.
/PRNewswire/ -- DelveInsight's High-grade Glioma Market Insights report includes a comprehensive understanding of current treatment practices, high-grade...
Lantern Pharma Inc. , an artificial intelligence company developing targeted and transformative cancer therapies using its proprietary AI and machine learning platform, RADR®, with multiple...
LP-184 is being studied in a first-in-human Phase 1 clinical trial, having been developed with guidance from Lantern’s AI Platform, RADR®, as a potential therapy for a wide range of advanced...
This is the second IND Clearance over the last 100 days for drug candidates that are being developed using guidance from Lantern’s AI Platform, RADR®. LP-284 is the second of Lantern’s...
18.09.2023 - Lantern Pharma Inc. (NASDAQ: LTRN), an artificial intelligence (AI) company developing targeted and transformative cancer therapies using its proprietary AI and machine learning (ML) platform, RADR, with multiple clinical stage drug programs, today ... Seite 1